Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 2
2010 2
2011 2
2012 8
2013 5
2014 7
2015 16
2016 12
2017 8
2018 7
2019 16
2020 20
2021 30
2022 32
2023 27
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, Shi M, Tan J, Zhang M, Xiao X, Xia J, Ma S, Qiao J, Yan Z, Li H, Pan B, Sang W, Li D, Li Z, Zhou J, Huang H, Liang A, Zheng J, Xu K. Qi Y, et al. Among authors: sang w. Blood. 2022 Jun 9;139(23):3376-3386. doi: 10.1182/blood.2021013733. Blood. 2022. PMID: 35338773 Free PMC article. Clinical Trial.
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Wang Y, et al. Among authors: sang w. J Clin Oncol. 2022 Jul 10;40(20):2246-2256. doi: 10.1200/JCO.21.01676. Epub 2022 Mar 25. J Clin Oncol. 2022. PMID: 35333600 Clinical Trial.
Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, Cao J, Li D, Cheng H, Sang W, Zhu F, Sun H, Chen W, Qi K, Yan D, Qiu T, Qiao J, Yao R, Liu Y, Wang X, Zhang Y, Peng S, Huang CH, Zheng J, Li Z, Chang AH, Xu K. Xia J, et al. Among authors: sang w. J Clin Oncol. 2023 May 10;41(14):2583-2593. doi: 10.1200/JCO.22.01824. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881785 Free PMC article. Clinical Trial.
Coenzyme-Catalyzed Electro-RAFT Polymerization.
Sang W, Xu M, Yan Q. Sang W, et al. ACS Macro Lett. 2017 Dec 19;6(12):1337-1341. doi: 10.1021/acsmacrolett.7b00886. Epub 2017 Nov 16. ACS Macro Lett. 2017. PMID: 35650813
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.
Bachy E, Savage KJ, Huang H, Kwong YL, Gritti G, Zhang Q, Liberati AM, Cao J, Yang H, Hao S, Hu J, Zhou K, Petrini M, Russo F, Zhang H, Sang W, Ji J, Ferreri AJM, Damaj GL, Liu H, Zhang W, Ke X, Ghiggi C, Huang S, Li X, Yao H, Paik J, Novotny W, Zhou W, Zhu H, Zinzani PL. Bachy E, et al. Among authors: sang w. Blood Adv. 2023 Aug 22;7(16):4435-4447. doi: 10.1182/bloodadvances.2022009575. Blood Adv. 2023. PMID: 37276067 Free PMC article. Clinical Trial.
184 results